The past, present and future challenges in epilepsy related and sudden deaths and biobanking.
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The cause of death is the aetiologically specific disease or injury that initiated the sequence of physiologic events leading directly to death. Examples of aetiologically specific causes of death include idiopathic epilepsy, atherosclerotic cardiovascular disease, drowning, and blunt force trauma. Mechanisms of death, the intervening steps that link the cause to the death, are the altered physiology or biochemistry through which the cause exerts its lethal effect and are not aetiologically specific (i.e. they can be due to many underlying aetiologies). Because the physiology of organ systems is complex and intertwined, there is never just one mechanism. Pulmonary oedema, cerebral hypoxia-ischaemia, arrhythmia and seizure are mechanisms of death. Each of these mechanisms may be happening during the death of a person with epilepsy. Pulmonary oedema is a finding that should be documented when present in ERD but is non-specific and it is recommended that this is not used in isolation as the cause of death in a patient with epilepsy.
Because there is often little evidence at post-mortem examination to determine when a seizure has occurred, it is often impossible to be certain that epilepsy was the cause of death in an unwitnessed case. When a person with epilepsy dies suddenly and is found to have another potentially lethal disease (e.g. Coronary artery disease), the Medical Examiner must weigh which aetiology was the more likely cause of death using details from the investigation and post-mortem examination.
Pulmonary oedema and tongue bites, particularly lateral tongue bites, are considered suggestive but not pathognomonic for seizure since they may be due to other aetiologies [19, 20] . Even a description of terminal seizure-like activity is not specific since persons dying of other diseases may have such activity without established epilepsy. Therefore, medical history and circumstances of death are critical to the final evaluation in any case. Absolute certainty of the cause is not needed for competent death certification. Once the Medical Examiner or Coroner has explored and excluded potential causes unrelated to epilepsy, through detailed investigation and complete post-mortem examination, the sudden death of a person with epilepsy is most likely caused by epilepsy.
The choice of wording for the death certificate varies widely between jurisdictions and between individuals within jurisdictions. Inconsistencies and lack of standardisation of wording remain widespread [6, 21] limiting our ability to track SUDEP rates over time. Despite the ubiquitous reference to SUDEP as a cause of death in the literature, it is an acronym that describes the circumstances of death; sudden, in a person with epilepsy, not due to an unnatural cause (e.g. not trauma or drowning), not the result of status epilepticus, and in the setting of a negative postmortem examination (i.e. no obvious toxicological or other anatomic cause identified) (Nashef, 1997) . Some Medical Examiners and Coroners are resistant to using SUDEP as a cause of death statement and favour use of the specific aetiology (epilepsy) instead. Unfortunately, the sudden
nature of the death is therefore often omitted from the cause statement, making identification and ascertainment of SUDEP cases for epidemiology and research difficult. Nevertheless although rarely used in previous decades [22] , 'SUDEP' is now more commonly recognized as an entity and listed on death certificates [23] and accepted as a valid diagnosis [11, 22] .
Neuropathology in SUDEP: Why it is needed
The primary objectives of the neuropathological examination in an ERD are to (i) exclude any unexpected cause of death, (ii) detect any underlying lesion causing the epilepsy and (iii) explore any neuropathological consequences of chronic or recent seizure activity. No neuropathological feature can establish a seizure as the mechanism of death. Furthermore, epilepsy is a clinical diagnosis supported by EEG and there are no specific neuropathological alterations that can categorically confirm epilepsy without confirmatory investigations undertaken during life. Neuropathological lesions that cause sudden death are often dramatic, macroscopically straightforward diagnoses; these include acute traumatic brain injury or spontaneous intracerebral haemorrhages [24] . More focal or subtle neuropathologies, such as fatal colloid cysts [25] or acute encephalitis [26, 27] , require a systematic, careful approach to brain examination with confirmatory immunohistochemistry or molecular studies, for example for viral markers, if necessary.
Among lesions that cause epilepsy, published series do not suggest that any single type is overrepresented in SUDEP (Table 2, Figure 2 ). The range of pathologies encompass those commonly encountered in surgical epilepsy series, including hippocampal sclerosis, cortical malformations such as focal cortical dysplasia (FCD) and low grade tumours [28] . Focal neuropathological abnormalities occur in ~50% of SUDEP autopsies ranging from 34 to 89% between larger SUDEP series (Table 2) .
Leestma, identified brain lesions in 60% of SUDEP cases compared to 11% in non-epilepsy autopsies [3] , but not all SUDEP studies support this [23, 29] and there are few post-mortem non-SUDEP epilepsy studies for comparison ( Figure 2 ). The variability in lesion detection may reflect the population demographics of the study as well as methodological differences between studies (e.g., macroscopically visible versus additional histological pathologies being reported). Identification of brain pathology pertaining to epilepsy is highly dependent on (i) the brain being examined in detail following a period of fixation [3, 30, 31] , (ii) the number of histological regional samples taken [31] , (iii) the level of scrutiny, for example if routine immunohistochemistry was carried out, as recommended in epilepsy surgical diagnostic protocols, [32] , and (iv) the experience and training of
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This article is protected by copyright. All rights reserved. the pathologist. In the forensic setting, the depth and detail of neuropathological investigation may be negatively affected by limited resources, including cost and access to special histologic techniques, neuropathology services and reporting time restrictions. Indeed, many epilepsy related pathologies are focal and visible only microscopically, some requiring specific immunohistochemistry to confirm diagnosis. Examples include milder or atypical forms of hippocampal sclerosis (ILAE type 3), granule cell dispersion [33] and hippocampal mossy fibre sprouting, considered to be a relatively specific secondary process in epilepsy (reviewed in [34]) (Figure 1c,d ). Mild malformations of cortical development (MCD), in particular mild MCD type II (heterotopic neurones in the white matter), have been reported in SUDEP [35] but are recognised to require quantitative immunohistochemistry confirmation with comparison to validated control ranges [36] . Currently we lack international agreement on precise diagnostic criteria for Mild MCD type II in surgical TLE or other brain regions [37] and because of this its recognition and reporting in ERD may widely vary. Even well-defined epileptogenic pathologies likely go undetected at post-mortem examination due to under-sampling.
For example, symptomatic FCD are not infrequently MRI 'occult' even with modern neuroimaging [38] (Figure 1e ,f); such lesions are typically macroscopically less visible with absent hallmark features, as regions of cortical thickening or blurring of the grey-white matter interface [37] . Access to clinical notes and any localising investigations (e.g. EEG, seizure semiology, MRI, PET findings) is good practice and may help to focus the pathologist on the epileptogenic zone and anecdotally can aid in the identification of underlying pathology, although data is lacking to prove this increases overall lesion detection rate. Given these methodological approaches that may influence the sensitivity of the post-mortem, there is lack of clarity from the available neuropathological series as to whether structural brain lesions are more frequent in SUDEP than epilepsy without SUDEP and therefore if symptomatic epilepsy compared to idiopathic/genetic causes represents a higher risk.
Regional Neuropathology -insights into mechanisms in SUDEP
Repetitive seizures can initiate molecular signals and cellular processes that ultimately alter the brain structure in terms of neuronal loss, gliosis [39] , microgliosis and inflammation [40], blood brain barrier breakdown [41] , vascular changes and axonal reorganisation [42, 43] . These can occur in the area of seizure onset in focal epilepsies but widespread brain alterations in the cortex [44] , thalamus and cerebellum can be observed at post-mortem [45] . Many of these sequelae represent a 'pathological' repair process that can further alter the seizure threshold, as exemplified by astrogliosis [39] . One key question is whether specific or strategic patterns of epilepsy-related brain
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This article is protected by copyright. All rights reserved. injury occur in SUDEP which could increase vulnerability or mechanistically be relevant to the cause of death. Central autonomic networks and cardiorespiratory centres are obvious candidate areas to investigate [12, 46] . These include the insular cortex, prefrontal cortex, hippocampus and amygdala through their connections to the hypothalamus, pons and medulla [47] . Ictal autonomic phenomena, as urinary urge, piloerection, and heart rate changes arise due to excitation or inhibition of these brain regions and are particularly associated with limbic or TLE [48] . Neuropathology studies have focused on chronic structural alteration as well as acute pathology. Inherent caveats to SUDEP research include imprecise times of death as most are unwitnessed, the unanticipated nature of death that incurs logistical delays in brain removal, and lack of suitable controls groups such as nonepilepsy sudden deaths and non-SUDEP epilepsy cases of similar age and severity of epilepsy.
Brainstem: Central control of respiration is regulated by interconnected medullary nuclear groups
forming the ventral respiratory column [46] including the Bötzinger and pre-Bötzinger complex [49] and modulated by other brainstem networks including the medullary raphe [50] . Notably, in experimental models of SUDEP, cortical seizures initiated spreading depolarisations or ictal activity in these brainstem regions which resulted in cardiorespiratory arrest [51, 52] . In neurodegenerative conditions with accompanying central respiratory deficits, selective reduction of specific respiratory (somatostatin/neurokinin 1Receptor + ) nuclear groups occurs [53] , and in Sudden Infant Death Syndrome (SIDS), alterations to the medullary serotonergic neurones is observed [54] . In MRI studies, medullary volume loss, proposed to be secondary to sustained seizure propagation, is of potential relevance to ictal autonomic disturbances in SUDEP [55] but there are limited neuropathology studies investigating specific cellular alterations [56, 57] .
Amygdala: In TLE amygdala neuronal loss or sclerosis is variably present [58, 59] . Seizure spread or stimulation of the basolateral and lateral nucleus amygdala results in transient apnoea [60, 61] , the central nucleus of the amygdala being connected to brainstem cardio-respiratory and other autonomic nuclei; therefore, underlying amygdala pathology could be mechanistically relevant in SUDEP. A stereological study of the lateral nucleus of the amygdala confirmed significantly reduced neuronal density and higher astrocytic densities in SUDEP compared to non-epilepsy controls ( Figure   1i ,j) [62] ; this was more prominent in the left side and independent of hippocampal sclerosis but no significant alteration in the central nucleus was found. MRI studies in SUDEP show higher amygdala volumes on the right side compared to control [63] . A more recent pathology study, however, failed to confirm significant differences in density of GFAP + astroglia in the lateral, basal and accessory basal nucleus of the amygdala in SUDEP compared to controls [56] .
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Hippocampus:
There is no evidence that hippocampal sclerosis is more prevalent in SUDEP. HS is reported in up to 21% of 145 SUDEP cases [31] ((Table 2 , Figure 2 ), compared to 30.5% of 650 [64] and 45% of 235 epilepsy post mortems [65] . Some unexplained deaths in infancy and childhood may be seizure-related and unexpected deaths in young patients with febrile seizures may share similar pathogenetic mechanisms to SUDEP [66, 67] . Developmental lesions of the dentate gyrus of the hippocampus have been reported in SIDS including varying degrees of bi-lamination of the dentate gyrus, noted in 41% of 153 cases [68] . Similarly, hippocampal abnormalities, including excessive convolutions of the dentate gyrus, granule cell bilamination, folding of the subiculum, and hippocampal malrotation were associated with sudden death in children (>1 year old) with a history of febrile seizures [69, 70] . Hippocampal malrotation is a developmental anatomical variant, identified in 23% of the general population on MRI in one series and more commonly left sided [71] .
Malrotation of the hippocampus was found on MRI in 8.8% of patients with febrile status in the FEBSTAT study [72] with predilection for the left side, compared to 2.1% in their control groups [73] .
Hippocampal malrotation may represent a substrate to febrile seizure and epilepsy [74] and granule cell dispersion is postulated as a morphological biomarker in SIDS that could indicate impaired connectivity between the hippocampus and brainstem [68] or a manifestation of previous unrecognised ictal activity [75] . Granule cell dispersion, a common and often prominent feature in approximately 40% of adult TLE patients with hippocampal sclerosis [34] , was reported in only 4% of 145 SUDEP cases without sclerosis [31] . However, as no study has systematically evaluated SUDEP cases comparable to SIDS [68] [69] [70] or surgical studies [76] , this feature may be under-recognised.
Similarly, hippocampal malrotation of varying degrees occur in 9.7% of SUDEP cases independently of sclerosis, which was more common on the left side [31] . In a quantitative MRI study, increased hippocampal volumes in SUDEP were noted on the right side [63] . More systematic analysis of hippocampal pathology and any lateralisation is warranted in SUDEP to explore structural/developmental alterations predisposing to SUDEP as a surrogate biomarker.
Thalamus: A reduction of grey matter volume in the posterior thalamus was noted in SUDEP on quantitative MRI which is of potential significance as this region has roles in breathing inhibition following episodes of hypoxia [63] . Involvement of the posterior thalamus in seizure initiation and cardiovascular modulation [77] and altered connectivity between thalamus, brainstem and frontal cortex may be relevant in some patients at high risk for SUDEP [78] . In post-mortem studies, the severity of thalamic pathology, based on reduced synaptophysin immunolabelling and gliosis, correlates with duration of seizures [79] but regional patterns of thalamic vulnerability in SUDEP, including any predilection for pulvinar or posterior lobe, remains to be addressed.
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This article is protected by copyright. All rights reserved. Cerebellum: Macroscopic atrophy or selective Purkinje cell loss were reported in 29% and 12% of SUDEP subjects respectively [31] but in up to 57% of other SUDEP series [80] . By comparison In vivo MRI findings showed cerebellar atrophy in 22% to 36% of non-SUDEP epilepsy groups on MRI measurements [81] . The fastigial nucleus of the cerebellum in functional imaging studies has roles in normal autonomic regulation of baroreflexes [82] . Cerebellar damage has been implicated in SUDEP
[83] but requires more rigorous pathology and molecular assessment in order to identify its role in the pathogenesis of SUDEP.
Cerebral cortex : Left insular cortex damage has been reported in SUDEP and associated with autonomic instability [84] and is a candidate region for further study [85] , but the mechanisms by which these anatomical abnormalities relate to sudden death are unclear. Apart from documentation of acute neuronal changes (see below) in the insula, there are no neuropathological correlative studies.
SUDEP -evidence for acute brain injury
SUDEP may be the consequence of extensive, irreversible neuronal damage during a seizure, strategic injury in critical autonomic regions or the cumulative effects of recent poor seizure control [86] . Such cellular injury or neurochemical exhaustion could decompensate normal homeostatic, auto-resuscitative mechanisms following a fatal seizure. Acute eosinophilic neuronal change has been reported in up to half of SUDEP cases [31] , although with notable differences between series (Table 2) which may reflect to its varying extent and hence detection ( Figure 2 ). It primarily involves the hippocampus (CA1/subiculum) although widespread involvement including cortical laminar patterns can occur [35] . This non-specific cytopathic change likely reflects hypoxic and/or excitotoxic cellular stresses occurring acutely (rather than immediately) in the last six hours. Hypoxia in epilepsy reflects ictal hypoperfusion [87] , impaired central respiration/transient apnoea, external airway compromise during seizure or a synergistic interaction of these. Acute neuronal injury in SDUEP was significantly more frequent when seizure episodes occurred in the 24 h prior to death, the body was found in a prone position, external airways were obstructed, or brain swelling was present [31] . In sudden unexplained death in childhood, hyper-eosinophilic acute ischaemic neurones were identified at similar rates to controls groups with known cause of death [69] .
Investigations in SUDEP of markers of acute neuronal death (necrosis, apoptosis) or reversible injury, including cell-stress signals promoting neuronal survival (VEGF, JNK1-3 , BNDF) [88] , enable
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This article is protected by copyright. All rights reserved. more objective data regarding the type, severity and distribution of brain injury, and could aid in localising the epileptogenic zone and explore secondary effects of ictal discharges involving central autonomic networks [48] . Heat Shock Protein (HSP-70)-positive neurones in all hippocampal subfields were more frequent in SUDEP compared to non-epilepsy and other epilepsy sudden deaths; similar differences were not noted for c-JUN neuronal expression [57] . Labelling of insular cortex and brainstem nuclei with HSP-70 and c-JUN was also observed [57] . Hippocampal neuronal hypoxia-inducible factor 1-alpha (HIF1-α) and vascular endothelial growth factor (VEGF) expression, both upregulated in response to hypoxia, occur in SUDEP although did not significantly differ from control groups [89] . A more recent study identified fewer HIF1-α neurones in the parahippocampal gyrus in SUDEP compared to non-epilepsy sudden death controls but no differences in the hippocampus, amygdala or brainstem, where neurones in the pre-Bötzinger complex were labelled strongly [56] . Further investigations correlating evidence of neuronal injury with clinical and genetic variables and circumstantial evidence of death will be important to inform on mechanisms in SUDEP.
Seizure induced neuroinflammation [40]
and acute blood brain barrier dysfunction [41] pose obvious candidate mechanisms in SUDEP. Increased, but statistically non-significant, brain weights and brain swelling, likely due to acute cerebral oedema, occur in SUDEP ( Table 2) 
Cardiopulmonary pathology and investigations in SUDEP
Pulmonary pathology is a common autopsy finding in SUDEP ( Table 2 ) reported in 72% of cases, with the most frequent findings being pulmonary congestion or oedema [90] . Although the incidence of post-ictal pulmonary oedema has been debated [91] , radiographic evidence was reported in 29% of patients following GTCS [92] . The pathogenic mechanisms of oedema following GTCS are not understood, and include increased sympathetic drive, mediated by the medulla and hypothalamus, altered hydrostatic pressures and increased pulmonary capillary permeability ('neurogenic
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This article is protected by copyright. All rights reserved. significance of these unexpected findings. Ictal disturbance in cardiac electrophysiology that induces dysrhythmias has long been considered a candidate mechanism of death in SUDEP [94] . Further, several ion channels have shared expression in brain and heart and cardiac genes associated with long QT syndrome (LQT), bradycardia, and SCD (KCNQ1, KCNH2, SCN5A, RYR2, HCN4) can cause both epilepsy and arrhythmias or increase the risk of seizure-induced arrhythmias and have been linked to SUDEP (reviewed in [5] and see section below) ( Table 3) .
Genetics of SUDEP and the molecular autopsy
In cases where the scene investigation, autopsy and toxicological studies do not reveal a probable or definite cause of death, post-mortem genetic testing can reveal a variant or mutation that could cause sudden death. These 'molecular autopsies' emerged from studies in which sudden cardiac death was suspected but only confirmed when post-mortem DNA analysis revealed genetic findings that established the likely mechanism of death. De novo or known pathogenic mutations in cardiac channelopathy or cardiomyopathy genes were found in 27% of children and young adults with unexplained sudden cardiac death [95] . While molecular autopsy is well established in evaluating cases of suspected sudden cardiac death, its role in defining the mechanism of death in epilepsy patients remains less well defined. Unlike sudden cardiac death, where pathogenic variants in genes that modulate the cardiac rhythm and myocardium are associated with sudden death and have a well-characterized lethal mechanism, defining a SUDEP gene is more challenging. In the largest study to date, 61 SUDEP cases underwent post-mortem whole exome sequencing. The investigators identified mutations in cardiac arrhythmia (all long QT) genes (7%), candidate pathogenic variants in dominant cardiac arrhythmia genes (15%) and mutations or candidate pathogenic variants in dominant epilepsy genes in 25% [96] . The unanswered question is the potential pathogenic relationship and role of these mutations in SUDEP.
Some genetic mutations are associated with an increased risk of SUDEP in humans and in some animal models of SUDEP. However, most of these mutations are established causes of epilepsy that are often treatment-resistant and associated with frequent GTCS (e.g., SCN1A, SCN8A, DEPDC5, dup15q; Table 3 ). The epileptic encephalopathies are associated with high rates of sudden death and status epilepticus [97] . In Dravet syndrome [98] , the mortality rate/1000-person-years was 15.8
and SUDEP rate was 9.3/1000-person-years. These rates are more than 10-fold higher than other paediatric epilepsies but similar to cohorts of adults with refractory epilepsy being evaluated for surgery (6-9/1000-person-years) [99] .
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The association of these genes with SUDEP could result solely from their role in causing severe epilepsy with frequent convulsive seizures and status epilepticus (e.g., SCN1A, SCN8A, dup15q) or epilepsy of variable severity (e.g., DEPDC5). However, specific genetic mutations may also independently contribute to the mechanism of death by facilitating autonomic instability, cardiac or respiratory dysfunction, or more prolonged postictal depression of arousal following a seizure or interfering with post-ictal autonomic recovery. Experimental models of Dravet syndrome reveal parasympathetic hyperactivity accompanies SUDEP and death can be prevented by parasympathetic blockade [100] . The relevance of this to human Dravet patients is uncertain as we lack autonomic data related to SUDEP, Dravet syndrome, and the broader epilepsy population. Marked sympathetic hyperactivity (elevated electrodermal activity) was documented post-ictally in a 20-
year-old SUDEP case (Picard et al 2017 Neurology In press). Sympathetic hyperactivity is well documented after most GTCSs in animals and humans. The mechanism of death in SUDEP may be related to postictal abnormalities of both parasympathetic [101] (e.g., bradycardia, hypotension) and sympathetic systems [5] .
The challenges in linking an epilepsy gene to SUDEP are highlighted by DEPDC5. This gene codes for a member of the IML1 protein family involved in G-protein signalling networks. The protein coded by DEPDC5 is a component of the GATOR1 complex that inhibits the mTORC1 pathway and can cause autosomal dominant familial focal epilepsy of variable severity. Pathogenic variants of DEPDC5 were enriched in the largest genetic study of a SUDEP cohort [96] . In a series of 61 SUDEP cases, five cases had DEPDC5 variants; three were nonsense mutations that were very likely pathogenic while two were missense variants, one of which is highly conserved in evolution. Yet DEDPC5 is the most common gene associated with familial focal epilepsy and is a common gene for sporadic focal epilepsy [102] . The challenges of differentiating genetic from other factors in the mechanism of death is exemplified by the two brothers with DEPDC5 mutations who both died from SUDEP but both had histories of AED nonadherence [103]. Since DEPDC5 patients often have frontal lobe foci and frontal lobe deficits, this can potentially impair planning and judgement, and this gene may increase SUDEP risk by causing treatment-resistant epilepsy as well as increasing the risk of life-style factors such as sleep deprivation, medication nonadherence and excess alcohol use.
SUDEP is not limited to treatment resistant epilepsies. SUDEP rarely complicates benign epilepsy of childhood with centrotemporal spikes and a history of convulsions not treated with antiepileptic drugs [104] . Further, one third of young children who die suddenly and have unrevealing
comprehensive death investigation, have a history of febrile seizures (ten-fold greater than the general population), suggesting seizure as a mechanism of death [67] . Thus, any patient with seizures is likely at increased risk for SUDEP post-ictally. Larger genetic studies are needed comparing SUDEP cases and control epilepsy populations matched for epilepsy severity, to determine if epilepsy genes increase SUDEP risk beyond the increased risk related to epilepsy severity.
As detailed above SUDEP is also associated with variants and mutations of neuro-cardiac channelopathy genes. The presence of LQT gene mutations in SUDEP suggests that a seizure could provoke a lethal cardiac arrhythmia, or sudden cardiac death could occur independently of a seizure. wave depression. These are less often associated with mutations in cardiac genes than torsade des pointes ventricular tachyarrhythmias. However, abnormalities in cardiac repolarization on ECG are more frequent in SUDEP than control epilepsy cases [107], suggesting a potential role of cardiac gene variants in SUDEP. As noted above, pathogenic and rare variants of cardiac channel genes are found in SUDEP cases [108]. Moreover, all channelopathy genes are expressed to some extent in the brain, including the brainstem. Thus, if these cardiac channelopathy genetic variants increase SUDEP risk, they could do so by alterations in the heart or brain, or both organs. The extremely rare occurrence of ventricular tachyarrhythmias in recorded SUDEP cases, or during seizures recorded in epilepsy monitoring units, suggest that if cardiac channel genes contribute to SUDEP pathogenesis, it may be via a different mechanism than their role in sudden cardiac death. Finally, some or many variants in cardiac genes may be unrelated to SUDEP pathogenesis.
The future and biobanking in SUDEP
There is current momentum from professional groups, as well as patient support groups, to move from mere recognition and documentation of SUDEP to identifying its causes and preventing its
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occurrence [109] . Despite an initial 'head start' by pathologists in recognising SUDEP, human tissue and cell based research programmes in ERD have somewhat lagged behind. The reasons are complex and manifold: (i) lack of clinical recognition and importance of the problem to allocate proportionate research funding in this area, (ii) establishing research collections in forensic setting where priorities and human tissue legislation is primarily geared toward establishing cause of death, with limited or restricted capacity to interact with research programmes, (iii) problems obtaining consent from immediately bereaved families, (iv) lack of easy access to a local or referral neuropathology services in some regions [16] , (v) problems with post-mortem decomposition of autopsy tissues [80] with many epilepsy research programmes focussing resources on optimally preserved surgical tissues, (vi) lack of sufficient numbers of suitable control cases and tissues, (vii) lack of standardised guidance documents for conducting SUDEP autopsies, the core practice of which can vary between regions and jurisdictions. This last point is pertinent, as despite a flurry of clinical practice documents on SUDEP aimed at neurologists and health care professionals (14 from the first half of 2017 alone [6, 7, 9, [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] there are very few directed at the pathologist regarding the elements and scope of the post-mortem examination. There are no consensus international best practice guidelines (in contrast to surgical epilepsy neuropathology practice [32, 33, 37] and informal enquiry indicates that very few countries have any form of autopsy guidelines for investigations in ERD. In the UK guidance documents for the approach to post-mortem examination, tissue sampling protocols ( Figure 1 ; Table 4 ) and classification of cause of death in suspected epilepsy and sudden cardiac cases are issued by the Royal College of Pathologists series (https://www.rcpath.org/profession/clinicaleffectiveness/clinical-guidelines/autopsy-guidelines.html) ; these provide guidelines and do not mandate practice and are based on current evidence available in ERD and SUDEP.
In establishing the Centres for SUDEP research [121] , the extent of the logistical problems and existing barriers to biobanking in ERD and SUDEP became apparent. These obstacles need to be addressed in the future and invested in to accelerate research into this condition. All biobanking should be conducted in full agreement with Coroners and Medical Examiners and following discussion and informed consent of the families (Figure 4) . Local practical and economical strategies to more accurately determine the cause of death in ERD should utilise regional expertise in neuro and cardiac pathology to augment the investigation with timely and detailed reports (Figure 4 ). Postmortem imaging, including MRI, CT and angiography is likely to play an increasing role in sudden death examination [122, 123] , where it may supplement standard autopsy procedures by revealing lesions difficult to assess by macroscopic examination. There is no published study applying postmortem imaging in ERD, however, high resolution MRI of whole brains or regions provides more
This article is protected by copyright. All rights reserved. detailed information of structural brain abnormalities enabling correlation with histological findings as ongoing areas of research [124, 125] . Prospective collection of DNA from brain, heart and lungs could also expand the range and scope of investigations. Techniques such as single cell RNAseq, proteomics usually requiring fresh frozen tissue, will provide complementary data on gene expression ; however, with newer technologies these methods are feasible with even formalin fixed, paraffin-embedded (FFPE) [126] . Greater availability of bio-specimens could facilitate numerous studies, including 1) systematic comparison of DNA exomes derived from blood and brain to examine the role of possible somatic mutations, 2) brainstem RNAseq in areas of interest (e.g., medullary raphe and pre-Bötzinger nuclei), 3) detailed examination of the cardiac conduction system. Such systematic tissue biobanking may enable better stratification of cause of death in SUDEP through integrated clinical, imaging, pathological and molecular diagnosis (Figure 4 ).
In summary, the evidence indicates that SUDEP is a heterogeneous condition in terms of both the underlying epilepsy neuropathology, genetics as well as mechanism of death. SUDEP at present provides a convenient 'umbrella' term under which to collect, stratify and further investigate these cases to shed light on any divergent or convergent pathogenetic mechanisms. Hopefully, in the future, epilepsy centres, neuropathologists, cardiac pathologists and medical examiners, coroner offices, and government funding agencies will collaborate in establishing international biorepositories to advance SUDEP research.
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This article is protected by copyright. All rights reserved. (1), temporal cortex (2), amygdala (3), thalamus (4) hippocampus from both sides and at several levels if indicated (5) and insular cortex with basal ganglia (6); see Table 4 for details of coronal levels and other recommended or essential samples as part of the routine neuropathology examination. C: Mild granule cell dispersion in SUDEP case. E. Mossy fibre sprouting in the hippocampus with ZnT3 immunostaining in SUDEP E: Temporal lobe cortex from a patient with a SUDEP. Macroscopic examination of the brain was unremarkable but samples from the left hemisphere showed regions of focal cortical dysplasia type IIA. This was confirmed with immunohistochemistry for neurofilament (shown in F). Red triangles represent data from reported series (as detailed in Table 2 ) and the black line is the average for all SUDEP series. 'Inflammatory' in this context refers to inflammatory diagnosis at autopsy as meningoencephalitis. This is compared to data from epilepsy PM series (*these also include some SUDEP cases) (Green triangle) [65, 127] and to surgical series (Blue triangle; data from the European Epilepsy Brain Bank of over 3,000 cases). Vision of future post-mortem examinations in epilepsy related deaths with intergrated clinicalpathology-genetics classifications and stratification of cause of death and intergration with research biobanks. *A SUDEP gene could be defined as a gene mutation of pathogenic variant that causes epilepsy and increases the SUDEP risk via the central or peripheral nervous system or end-organ effects on respiratory, cardiac or other autonomic functions [5] . ~ Some post-mortem investigations would be carried out as relevant on a case by case basis. COD= cause of death, SCD = sudden cardiac death
Category of sudden death

Definition / criteria
Post mortem findings pertaining to cause of death DEFINITE SUDEP Sudden, unexpected, witnessed or unwitnessed. Exclude traumatic causes and drowning (death in 'benign' circumstances). Clinical diagnosis of epilepsy*. Status epilepticus cases excluded (seizure ≥ 30 min or serial seizures without recovery between).
No cause of death identified (including toxicology, histology and neuropathology examination).
DEFINITE SUDEP PLUS
Criteria as for Definite SUDEP.
Concomitant condition identified: not proven to be the cause of death but may have contributed.
PROBABLE SUDEP
Not conducted or Elements of the examination incomplete (e.g. no neuropathology or toxicology screen).
POSSIBLE SUDEP
A competing cause of death is identified at post-mortem examination.
SUDDEN DEATH WITH SYMPTOMATIC SEIZURE
Clinical diagnosis of epilepsy lacking* (e.g. alcohol withdrawal seizures).
Pathology relating to underlying condition may be found. Table 1 . Categories of Sudden Death in Epilepsy (adapted from [11, 13] ). * Epilepsy defined as ≥ 2 unprovoked seizures at least 24 hours apart or a single unprovoked seizure with an enduring risk for further seizures.
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This article is protected by copyright. All rights reserved. Table 2 . Pathology studies in SUDEP based on series with more than one case and the positive findings are detailed. CVA = Cerebro-vascular accident, FCD= focal cortical dysplasia, HS= hippocampal sclerosis, NOS= not otherwise specified, TBI = traumatic brain injury, TS = Tuberous Sclerosis, VM= vascular malformation, PM=post-mortem, ICH = intra cranial haemorrhage, ys = years. Studies with details of macro and/or histological findings are included.
Likely SUDEP Gene
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HCN2 [135] Hyperpolarization activated cyclic nucleotide gated potassium channel 2; Contributes to spontaneous rhythmic activity in heart (sinoatrial node) and brain
Generalized epilepsy
Brain, heart, lung KCNT1 [138] Outwardly rectifying potassium channel subunit Focal epilepsy, EE Brain, lung, heart
Chromosomal disorders* Dup15q11 [99] supernumerary isodicentric chromosome 15; extra copies of UBE3A (Angelman syndrome) and GABRB3 (GABA receptor) EE; variable epilepsy phenotype UBE3A -brain, heart, lung GABRB3 -brain, heart, lung 5q14.3 deletion [139] Haploinsufficiency of MEF2C (role in myogenesis) and EFNA5receptor protein-tyrosine kinases involved in neurodevelopment Variable severity of epilepsy and neurodevelopmental disability MEF2C -brain, heart, lung EFNA5 -brain, heart, lung Table 3 . Genes implicated in SUDEP. ES -epilepsy severity; EE -epileptic encephalopathy; *No animal models exist for these genetic disorders and with most genes, it is uncertain if the risk of SUDEP is solely accounted for by the severity of epilepsy and developmental delays
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